Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ECOZA vs AUKELSO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.
Selective inhibitor of the mammalian target of rapamycin (m TOR) kinase, specifically the m TORC1 complex, leading to inhibition of cell proliferation, angiogenesis, and glucose uptake.
Topical treatment of tinea pedis, tinea cruris, tinea corporis, tinea versicolor, and cutaneous candidiasis
Advanced renal cell carcinoma,Progressive neuroendocrine tumors of pancreatic origin,Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis,Advanced neuroendocrine tumors of gastrointestinal or lung origin
For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.
400 mg orally twice daily with food.
Terminal elimination half-life is approximately 24–30 hours, allowing for once-daily dosing.
Terminal elimination half-life approximately 24 hours (range 20–28 h), supports once-daily dosing; prolonged in severe hepatic impairment.
Not extensively metabolized; minimal systemic absorption after topical application.
Primarily metabolized by CYP3A4
Primarily hepatic metabolism; <1% excreted renally as unchanged drug. Fecal excretion accounts for ~57% of metabolites.
Primarily hepatic metabolism with biliary excretion; ~20% renal elimination of unchanged drug. Fecal excretion of metabolites accounts for ~65% of total clearance.
Approximately 89–93% bound to plasma proteins, primarily albumin.
High protein binding, approximately 99.8%, primarily to albumin and alpha-1-acid glycoprotein.
Apparent volume of distribution is approximately 2–3 L/kg, indicating extensive tissue penetration.
Volume of distribution ~0.15 L/kg (range 0.12–0.18 L/kg), indicating limited extravascular distribution, predominantly confined to plasma and extracellular fluid.
Oral bioavailability is approximately 37% (range 20–70%) due to first-pass metabolism; topical bioavailability is negligible systemically.
Oral bioavailability ~85%; unaffected by food.
No dosage adjustment required for renal impairment. Systemic absorption is minimal after topical or intravaginal use.
GFR ≥60 m L/min: no adjustment; GFR 30-59 m L/min: 200 mg twice daily; GFR <30 m L/min: 200 mg once daily; hemodialysis: 200 mg three times weekly after dialysis.
No dosage adjustment required for hepatic impairment due to minimal systemic absorption.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg twice daily; Child-Pugh C: 200 mg once daily.
Safety and efficacy in pediatric patients have not been established for vaginal use. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily; duration based on clinical response. Weight-based dosing not applicable.
Body weight 10-20 kg: 200 mg twice daily; 20-40 kg: 300 mg twice daily; ≥40 kg: 400 mg twice daily.
No specific dose adjustment required; use same dosing as for younger adults. Monitor for local irritation or adverse effects.
No specific dose adjustment based on age alone; monitor renal function and adjust per renal guidelines.
None
No FDA black box warning.
For external use only; avoid contact with eyes; discontinue if hypersensitivity occurs.
Non-infectious pneumonitis,Infections (including opportunistic infections),Hypersensitivity reactions,Renal impairment,Metabolic effects (hyperglycemia, hyperlipidemia),Interstitial lung disease,Hemorrhagic events,Wound healing complications,Immunosuppression,Increased risk of thrombosis
Known hypersensitivity to imidazole antifungals or any component of the formulation
Hypersensitivity to everolimus or any component of the formulation
No clinically significant food interactions for topical econazole nitrate. Avoid alcohol if using oral antifungal concurrently (not applicable here).
Avoid grapefruit and grapefruit juice; may increase drug levels. Take with or without food, but high-fat meals may increase absorption. Avoid alcohol due to hepatotoxicity risk.
ECOZA (econazole nitrate) is pregnancy category C. First trimester: no adequate studies; avoid unless benefit outweighs risk. Second/third trimester: minimal absorption after topical application, unlikely to cause fetal harm; however, prolonged use near term is not recommended due to theoretical risk of premature ductus arteriosus closure if systemic absorption occurs.
First trimester: Avoid use due to potential for fetal harm based on animal studies showing developmental toxicity (including cardiovascular and skeletal malformations). Second and third trimesters: Use only if maternal benefit outweighs fetal risk; may cause fetal growth restriction or oligohydramnios in off-label experience. No adequate human data.
Not known if econazole is excreted in human milk. M/P ratio not available. Due to low systemic absorption after topical use, risk to nursing infant is considered low. Caution if applied to breast area; avoid infant ingestion.
No human data on milk excretion or infant effects. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., immunosuppression), advise against breastfeeding during treatment and for 2 weeks after last dose.
No dose adjustment needed. Pharmacokinetic changes in pregnancy (e.g., increased skin blood flow, hydration) may slightly alter absorption but clinical significance is minimal. Use standard topical dosing as prescribed.
No established dose adjustment in pregnancy. Consider reduced dosing if increased clearance occurs (second trimester). Monitor drug levels if available; otherwise, adjust based on clinical response and toxicity.
Ecoza (econazole nitrate) is a topical azole antifungal. Avoid use on open wounds or broken skin. Apply once daily for 4 weeks for tinea pedis; 2 weeks for tinea cruris/corporis. Do not use occlusive dressings. Monitor for local irritation, burning, or allergic contact dermatitis.
Monitor for QT prolongation, electrolyte abnormalities, and hepatotoxicity. Adjust dose in renal impairment (Cr Cl <30 m L/min). Avoid use with strong CYP3A4 inhibitors or inducers. Note potential for phototoxicity; advise sun avoidance.
Apply a thin layer to cleaned, dry affected area and surrounding skin once daily or as directed.,Wash hands before and after application unless treating hands.,Use for the full prescribed duration even if symptoms improve to prevent recurrence.,Avoid contact with eyes, mouth, or mucous membranes. If contact occurs, rinse with water.,Do not cover the treated area with bandages or wrappings unless instructed by your doctor.,Inform your doctor if symptoms persist after 2 weeks or worsen, or if severe irritation occurs.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not change dose or stop without consulting doctor.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception during therapy and for 1 month after last dose.,Report symptoms like irregular heartbeat, fainting, severe nausea/vomiting, or yellowing of skin/eyes immediately.,Use sunscreen and protective clothing; avoid sun exposure, even through glass.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ECOZA vs AUKELSO, answered by our medical review team.
ECOZA is a Topical Antifungal that works by Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.. AUKELSO is a Topical Antifungal that works by Selective inhibitor of the mammalian target of rapamycin (m TOR) kinase, specifically the m TORC1 complex, leading to inhibition of cell proliferation, angiogenesis, and glucose uptake.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ECOZA and AUKELSO depend on the specific clinical indication. These are both Topical Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ECOZA is: For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.. The standard adult dose of AUKELSO is: 400 mg orally twice daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ECOZA and AUKELSO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ECOZA is classified as Category C. ECOZA (econazole nitrate) is pregnancy category C. First trimester: no adequate studies; avoid unless benefit outweighs risk. Second/third trimester: minimal absorption after topic. AUKELSO is classified as Category C. First trimester: Avoid use due to potential for fetal harm based on animal studies showing developmental toxicity (including cardiovascular and skeletal malformations). Second and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.